As of Dec 12
| +0.30 / +0.91%|
The 34 analysts offering 12-month price forecasts for AstraZeneca have a median target of 36.28, with a high estimate of 50.17 and a low estimate of 24.92. The median estimate represents a +8.57% increase from the last price of 33.42.
The current consensus among 39 polled investment analysts is to Buy stock in AstraZeneca. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.